Annual Statements Open main menu

APTARGROUP, INC. - Quarter Report: 2014 September (Form 10-Q)

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[X]         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2014

 

OR

 

[ ]          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM             TO           

 

____________________________________________________________________________

 

COMMISSION FILE NUMBER 1-11846

 

AptarGroup, Inc.

 

DELAWARE

 

36-3853103

(State of Incorporation)

 

(I.R.S. Employer Identification No.)

 

475 WEST TERRA COTTA AVENUE, SUITE E, CRYSTAL LAKE, ILLINOIS 60014

 

815-477-0424

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer þ

 

Accelerated filer ¨

 

Non-accelerated filer ¨

 

Smaller reporting company ¨

 

 

 

 

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date

 

Class

 

Outstanding at November 3, 2014

Common Stock, $.01 par value per share

 

64,727,773 shares

 



Table of Contents

 

 

 

AptarGroup, Inc.

 

Form 10-Q

 

Quarter Ended September 30, 2014

 

INDEX

 

 

Part I.

FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

 

 

 

 

Condensed Consolidated Statements of Income - Three and Nine Months Ended September 30, 2014 and 2013

1

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2014 and 2013

2

 

 

 

 

Condensed Consolidated Balance Sheets – September 30, 2014 and December 31, 2013

3

 

 

 

 

Condensed Consolidated Statements of Changes in Equity – Nine Months Ended September 30, 2014 and 2013

5

 

 

 

 

Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2014 and 2013

6

 

 

 

 

Notes to Condensed Consolidated Financial Statements

7

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

 

 

 

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

24

 

 

 

Item 4.

Controls and Procedures

24

 

 

 

Part II.

OTHER INFORMATION

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

25

 

 

 

Item 6.

Exhibits

25

 

 

 

 

Signature

26

 

i



Table of Contents

 

PART I – FINANCIAL INFORMATION

 

ITEM 1.  FINANCIAL STATEMENTS (UNAUDITED)

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

In thousands, except per share amounts

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

651,942

 

$

623,644

 

$

1,998,624

 

$

1,882,718

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

Cost of sales (exclusive of depreciation and amortization shown below)

 

443,520

 

424,011

 

1,347,982

 

1,273,848

 

Selling, research & development and administrative

 

91,649

 

86,917

 

294,809

 

269,335

 

Depreciation and amortization

 

38,158

 

37,222

 

113,871

 

112,007

 

Restructuring initiatives

 

--

 

2,180

 

--

 

8,758

 

 

 

573,327

 

550,330

 

1,756,662

 

1,663,948

 

Operating Income

 

78,615

 

73,314

 

241,962

 

218,770

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

Interest expense

 

(5,332

)

(4,841

)

(15,459

)

(15,364

)

Interest income

 

1,386

 

576

 

3,449

 

2,271

 

Equity results of affiliates

 

(124

)

(286

)

(1,868

)

(609

)

Miscellaneous, net

 

(429

)

(437

)

(582

)

(1,070

)

 

 

(4,499

)

(4,988

)

(14,460

)

(14,772

)

 

 

 

 

 

 

 

 

 

 

Income before Income Taxes

 

74,116

 

68,326

 

227,502

 

203,998

 

 

 

 

 

 

 

 

 

 

 

Provision for Income Taxes

 

25,496

 

23,094

 

77,390

 

68,908

 

 

 

 

 

 

 

 

 

 

 

Net Income

 

$

48,620

 

$

45,232

 

$

150,112

 

$

135,090

 

 

 

 

 

 

 

 

 

 

 

Net (Income) Loss Attributable to Noncontrolling Interests

 

$

(25

)

$

32

 

$

(52

)

$

5

 

 

 

 

 

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc.

 

$

48,595

 

$

45,264

 

$

150,060

 

$

135,095

 

 

 

 

 

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc. per Common Share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.75

 

$

0.68

 

$

2.30

 

$

2.04

 

Diluted

 

$

0.73

 

$

0.67

 

$

2.21

 

$

1.98

 

 

 

 

 

 

 

 

 

 

 

Average Number of Shares Outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

64,886

 

66,092

 

65,225

 

66,222

 

Diluted

 

66,845

 

67,986

 

67,761

 

68,273

 

 

 

 

 

 

 

 

 

 

 

Dividends per Common Share

 

$

0. 28

 

$

0.25

 

$

0. 81

 

$

0.75

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

1



Table of Contents

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

In thousands

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Income

 

$

48,620

 

$

45,232

 

$

150,112

 

$

135,090

 

Other Comprehensive Income:

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

(118,758

)

45,344

 

(123,359

)

16,282

 

Changes in treasury locks, net of tax

 

6

 

9

 

18

 

39

 

Defined benefit pension plan, net of tax

 

 

 

 

 

 

 

 

 

Amortization of prior service cost included in net income, net of tax

 

51

 

61

 

157

 

183

 

Amortization of net loss included in net income, net of tax

 

658

 

1,039

 

1,987

 

3,111

 

Total defined benefit pension plan, net of tax

 

709

 

1,100

 

2,144

 

3,294

 

Total other comprehensive (loss) income

 

(118,043

)

46,453

 

(121,197

)

19,615

 

 

 

 

 

 

 

 

 

 

 

Comprehensive (Loss) Income

 

(69,423

)

91,685

 

28,915

 

154,705

 

 

 

 

 

 

 

 

 

 

 

Comprehensive (Income) Loss Attributable To Noncontrolling Interests

 

(29

)

30

 

(47

)

(2

)

 

 

 

 

 

 

 

 

 

 

Comprehensive (Loss) Income Attributable To AptarGroup, Inc.

 

$

(69,452

)

$

91,715

 

$

28,868

 

$

154,703

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

2



Table of Contents

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

In thousands

 

 

 

September 30,

 

December 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and equivalents

 

$

347,394

 

$

309,861

 

Accounts and notes receivable, less allowance for doubtful accounts of $4,215 in 2014 and $4,416 in 2013

 

468,182

 

438,221

 

Inventories

 

340,952

 

353,159

 

Prepaid and other

 

102,644

 

97,170

 

 

 

1,259,172

 

1,198,411

 

 

 

 

 

 

 

Property, Plant and Equipment:

 

 

 

 

 

Buildings and improvements

 

362,485

 

377,300

 

Machinery and equipment

 

1,951,876

 

1,982,195

 

 

 

2,314,361

 

2,359,495

 

Less: Accumulated depreciation

 

(1,505,822

)

(1,518,894

)

 

 

808,539

 

840,601

 

Land

 

22,475

 

24,061

 

 

 

831,014

 

864,662

 

 

 

 

 

 

 

Other Assets:

 

 

 

 

 

Investments in affiliates

 

6,053

 

8,243

 

Goodwill

 

339,275

 

358,865

 

Intangible assets, net

 

42,551

 

49,951

 

Miscellaneous

 

21,174

 

17,630

 

 

 

409,053

 

434,689

 

Total Assets

 

$

2,499,239

 

$

2,497,762

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

3



Table of Contents

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

(Unaudited)

 

In thousands, except per share amounts

 

 

 

September 30,

 

December 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Notes payable

 

$

243,983

 

$

138,445

 

Current maturities of long-term obligations

 

2,547

 

1,325

 

Accounts payable and accrued liabilities

 

385,343

 

403,051

 

 

 

631,873

 

542,821

 

 

 

 

 

 

 

Long-Term Obligations

 

355,583

 

354,814

 

 

 

 

 

 

 

Deferred Liabilities and Other:

 

 

 

 

 

Deferred income taxes

 

29,501

 

42,072

 

Retirement and deferred compensation plans

 

66,545

 

71,883

 

Deferred and other non-current liabilities

 

4,859

 

5,864

 

Commitments and contingencies

 

--

 

--

 

 

 

100,905

 

119,819

 

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

AptarGroup, Inc. stockholders’ equity

 

 

 

 

 

Common stock, $.01 par value, 199 million shares authorized; 86.0 and 85.4 million shares issued as of September 30, 2014 and December 31, 2013, respectively

 

859

 

853

 

Capital in excess of par value

 

539,055

 

493,947

 

Retained earnings

 

1,716,536

 

1,619,419

 

Accumulated other comprehensive (loss) income

 

(11,441

)

109,751

 

Less treasury stock at cost, 21.3 and 20.0 million shares as of September 30, 2014 and December 31, 2013, respectively

 

(834,729

)

(744,213

)

Total AptarGroup, Inc. Stockholders’ Equity

 

1,410,280

 

1,479,757

 

Noncontrolling interests in subsidiaries

 

598

 

551

 

 

 

 

 

 

 

Total Stockholders’ Equity

 

1,410,878

 

1,480,308

 

Total Liabilities and Stockholders’ Equity

 

$

2,499,239

 

$

2,497,762

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

4



Table of Contents

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

 

In thousands

 

 

 

AptarGroup, Inc. Stockholders’ Equity

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

Common

 

 

 

Capital in

 

Non-

 

 

 

 

 

Retained

 

Comprehensive

 

Stock

 

Treasury

 

Excess of

 

Controlling

 

Total

 

 

 

Earnings

 

Income/(Loss)

 

Par Value

 

Stock

 

Par Value

 

Interest

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance – December 31, 2012:

 

$

1,513,558

 

$

60,683

 

$

840

 

$

(625,401

)

$

430,210

 

$

608

 

$

1,380,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

135,095

 

 

 

 

 

 

 

 

 

(5

)

135,090

 

Foreign currency translation adjustments

 

 

 

16,275

 

 

 

 

 

 

 

7

 

16,282

 

Changes in unrecognized pension gains/losses and related amortization, net of tax

 

 

 

3,294

 

 

 

 

 

 

 

 

 

3,294

 

Changes in treasury locks, net of tax

 

 

 

39

 

 

 

 

 

 

 

 

 

39

 

Stock option exercises & restricted stock vestings

 

 

 

 

 

12

 

1

 

55,523

 

 

 

55,536

 

Cash dividends declared on common stock

 

(49,674

)

 

 

 

 

 

 

 

 

 

 

(49,674

)

Treasury stock purchased

 

 

 

 

 

 

 

(80,222

)

 

 

 

 

(80,222

)

Balance – September 30, 2013:

 

$

1,598,979

 

$

80,291

 

$

852

 

$

(705,622

)

$

485,733

 

$

610

 

$

1,460,843

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance – December 31, 2013:

 

$

1,619,419

 

$

109,751

 

$

853

 

$

(744,213

)

$

493,947

 

$

551

 

$

1,480,308

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

150,060

 

 

 

 

 

 

 

 

 

52

 

150,112

 

Foreign currency translation adjustments

 

 

 

(123,354

)

 

 

 

 

 

 

(5

)

(123,359

)

Changes in unrecognized pension gains/losses and related amortization, net of tax

 

 

 

2,144

 

 

 

 

 

 

 

 

 

2,144

 

Changes in treasury locks, net of tax

 

 

 

18

 

 

 

 

 

 

 

 

 

18

 

Stock option exercises & restricted stock vestings

 

 

 

 

 

6

 

1

 

45,108

 

 

 

45,115

 

Cash dividends declared on common stock

 

(52,943

)

 

 

 

 

 

 

 

 

 

 

(52,943

)

Treasury stock purchased

 

 

 

 

 

 

 

(90,517

)

 

 

 

 

(90,517

)

Balance – September 30, 2014:

 

$

1,716,536

 

$

(11,441

)

$

859

 

$

(834,729

)

$

539,055

 

$

598

 

$

1,410,878

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

5



Table of Contents

 

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

In thousands, brackets denote cash outflows

 

Nine Months Ended September 30,

 

2014

 

2013

 

 

 

 

 

 

 

Cash Flows from Operating Activities:

 

 

 

 

 

Net income

 

$

150,112

 

$

135,090

 

Adjustments to reconcile net income to net cash provided by operations:

 

 

 

 

 

Depreciation

 

109,821

 

108,259

 

Amortization

 

4,050

 

3,748

 

Stock based compensation

 

15,025

 

11,538

 

Provision for doubtful accounts

 

228

 

(516

)

Deferred income taxes

 

(12,701

)

(5,612

)

Defined benefit plan expense

 

12,622

 

14,531

 

Equity in results of affiliates in excess of cash distributions received

 

1,868

 

609

 

Changes in balance sheet items, excluding effects from foreign currency adjustments:

 

 

 

 

 

Accounts receivable

 

(57,220

)

(42,531

)

Inventories

 

(11,386

)

(27,168

)

Prepaid and other current assets

 

(14,984

)

(15,416

)

Accounts payable and accrued liabilities

 

5,236

 

8,544

 

Income taxes payable

 

(13,334

)

10,312

 

Retirement and deferred compensation plans

 

(9,803

)

(18,717

)

Other changes, net

 

20,426

 

11,850

 

Net Cash Provided by Operations

 

199,960

 

194,521

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

Capital expenditures

 

(125,465

)

(110,350

)

Disposition of property and equipment

 

1,002

 

2,207

 

Investment in unconsolidated affiliate

 

--

 

(13

)

Notes receivable, net

 

(2,820

)

(159

)

Net Cash Used by Investing Activities

 

(127,283

)

(108,315

)

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

Proceeds from notes payable

 

106,455

 

31,908

 

Proceeds from long-term obligations

 

2,816

 

--

 

Repayments of long-term obligations

 

--

 

(25,491

)

Dividends paid

 

(52,943

)

(49,674

)

Credit facility costs

 

(299

)

(498

)

Proceeds from stock option exercises

 

24,564

 

38,368

 

Purchase of treasury stock

 

(90,517

)

(80,222

)

Excess tax benefit from exercise of stock options

 

4,959

 

5,058

 

Net Cash Used by Financing Activities

 

(4,965

)

(80,551

)

 

 

 

 

 

 

Effect of Exchange Rate Changes on Cash

 

(30,179

)

12,441

 

 

 

 

 

 

 

Net Increase in Cash and Equivalents

 

37,533

 

18,096

 

Cash and Equivalents at Beginning of Period

 

309,861

 

229,755

 

Cash and Equivalents at End of Period

 

$

347,394

 

$

247,851

 

 

See accompanying Unaudited Notes to Condensed Consolidated Financial Statements.

 

6



Table of Contents

 

AptarGroup, Inc.

Notes to Condensed Consolidated Financial Statements

(Amounts in Thousands, Except Share and per Share Amounts, or Otherwise Indicated)

(Unaudited)

 

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

BASIS OF PRESENTATION

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries.  The terms “AptarGroup” or “Company” as used herein refer to AptarGroup, Inc. and our subsidiaries.  All significant intercompany accounts and transactions have been eliminated.

In the opinion of management, the Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented.  The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).  Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures made are adequate to make the information presented not misleading.  Also, certain financial position data included herein was derived from the Audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 but does not include all disclosures required by GAAP.  Accordingly, these Unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.  The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

 

ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates to the FASB’s Accounting Standards Codification.

In July 2013, the FASB issued authoritative guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.  This standard requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward.  The guidance is effective for the Company’s fiscal years beginning after December 15, 2013.  This standard did not impact our current year financial statements as this was already the Company’s existing reporting treatment.

In March 2013, the FASB issued authoritative guidance which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity.  Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or if a controlling financial interest is no longer held. The guidance is effective for the Company’s fiscal years beginning after December 15, 2013.  This standard has only a minimal impact on our current year financial statements.

In February 2013, the FASB issued authoritative guidance that amends the presentation of accumulated other comprehensive income and clarifies how to report the effect of significant reclassifications out of accumulated other comprehensive income.  The guidance requires footnote disclosures regarding the changes in accumulated other comprehensive income by component and the line items affected in the statements of earnings.  The adoption of this standard had no impact on the Unaudited Condensed Consolidated Financial Statements other than disclosure.  Additional information can be found in Note 6 of the Unaudited Notes to the Condensed Consolidated Financial Statements.

In January 2013, the FASB issued authoritative guidance requiring new asset and liability offsetting disclosures for derivatives, repurchase agreements and security lending transactions to the extent that they are offset in the financial statements or are subject to an enforceable master netting arrangement or similar agreement.  We do not have any repurchase agreements and do not participate in securities lending transactions.  Our derivative instruments are not offset in the financial statements. Accordingly, the adoption of this standard had no impact on the Unaudited Condensed Consolidated Financial Statements other than disclosure.  Additional information can be found in Note 7 of the Unaudited Notes to the Condensed Consolidated Financial Statements.

Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material impact on our Unaudited Condensed Consolidated Financial Statements.

 

INCOME TAXES

The Company computes taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned.  The income tax rates imposed by these taxing authorities may vary substantially.  Taxable income may differ from pretax income for financial accounting purposes.  To the extent that these differences create differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

In our determination of which foreign earnings are permanently reinvested in foreign operations, the Company considers numerous factors, including the financial requirements of the U.S. parent company and those of our foreign subsidiaries, the U.S. funding needs for dividend payments and stock repurchases, and the tax consequences of remitting earnings to the U.S.  From this analysis, current year repatriation decisions are made in an attempt to provide a proper mix of debt and stockholder capital both within the U.S. and for non-U.S. operations.  The Company’s policy is to permanently reinvest our accumulated foreign earnings and will only make a distribution out of current year earnings to meet the cash needs at the parent company. 

 

7



Table of Contents

 

As such, the Company does not provide for taxes on earnings that are deemed to be permanently reinvested.  Since no distribution to the U.S. of foreign earnings is expected in 2014, the effective tax rate for 2014 includes no tax cost of repatriation. Although the Company does not expect to repatriate foreign earnings back to the U.S. in 2014, dividends on certain earnings within Europe to our European holding company are expected to increase in 2014 as part of a legal reorganization of our non-U.S. subsidiaries.  Due to this legal reorganization, additional tax costs in the third quarter of 2014 were approximately $3.1 million, of which $2.8 million related to the change in our reinvestment assertion within Europe.

The Company provides a liability for the amount of tax benefits realized from uncertain tax positions.  This liability is provided whenever the Company determines that a tax benefit will not meet a more-likely-than-not threshold for recognition.  See Note 4 of the Unaudited Notes to the Condensed Consolidated Financial Statements for more information.

 

NOTE 2 - INVENTORIES

 

At September 30, 2014 and December 31, 2013, approximately 19% and 20%, respectively, of the total inventories are accounted for by using the LIFO method.  Inventories, by component, consisted of:

 

 

 

 

September 30,

 

December 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Raw materials

 

$

115,575

 

$

114,501

 

Work in process

 

103,262

 

108,924

 

Finished goods

 

130,055

 

137,591

 

Total

 

348,892

 

361,016

 

Less LIFO Reserve

 

(7,940

)

(7,857

)

Total

 

$

340,952

 

$

353,159

 

 

NOTE 3 – GOODWILL AND OTHER INTANGIBLE ASSETS

 

The changes in the carrying amount of goodwill since the year ended December 31, 2013 are as follows by reporting segment:

 

 

 

 

Beauty +

 

 

 

Food +

 

Corporate

 

 

 

 

 

Home

 

Pharma

 

Beverage

 

& Other

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Goodwill

 

$

181,002

 

$

159,949

 

$

17,914

 

$

1,615

 

$

360,480

 

Accumulated impairment losses

 

--

 

--

 

--

 

(1,615

)

(1,615

)

Balance as of December 31, 2013

 

$

181,002

 

$

159,949

 

$

17,914

 

$

--

 

$

358,865

 

Acquisition

 

--

 

--

 

--

 

--

 

--

 

Foreign currency exchange effects

 

(6,574

)

(12,383

)

(633

)

--

 

(19,590

)

Goodwill

 

$

174,428

 

$

147,566

 

$

17,281

 

$

1,615

 

$

340,890

 

Accumulated impairment losses

 

--

 

--

 

--

 

(1,615

)

(1,615

)

Balance as of September 30, 2014

 

$

174,428

 

$

147,566

 

$

17,281

 

$

--

 

$

339,275

 

 

The table below shows a summary of intangible assets as of September 30, 2014 and December 31, 2013.

 

 

 

 

 

 

September 30, 2014

 

December 31, 2013

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average

 

Gross

 

 

 

 

 

Gross

 

 

 

 

 

Amortization

 

Carrying

 

Accumulated

 

Net

 

Carrying

 

Accumulated

 

Net

 

Period (Years)

 

Amount

 

Amortization

 

Value

 

Amount

 

Amortization

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortized intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patents

 

7

 

$

18,282

 

$

(18,067

)

$

215

 

$

20,165

 

$

(19,732

)

$

433

 

Acquired technology

 

15

 

37,260

 

(5,589

)

31,671

 

40,546

 

(4,055

)

36,491

 

License agreements and other

 

5

 

33,490

 

(22,825

)

10,665

 

35,259

 

(22,232

)

13,027

 

Total intangible assets

 

10

 

$

89,032

 

$

(46,481

)

$

42,551

 

$

95,970

 

$

(46,019

)

$

49,951

 

 

Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2014 and 2013 was $1,283 and $1,266, respectively.  Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2014 and 2013 was $4,050 and $3,748, respectively.

 

Future estimated amortization expense for the years ending December 31 is as follows:

 

2014

 

$

1,291

             (remaining estimated amortization for 2014)

 

2015

 

4,960

 

 

2016

 

4,024

 

 

2017

 

3,338

 

 

2018 and thereafter

 

28,938

 

 

 

8



Table of Contents

 

Future amortization expense may fluctuate depending on changes in foreign currency rates.  The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, 2014.

 

NOTE 4 – INCOME TAX UNCERTAINTIES

 

The Company had approximately $6.6 and $8.0 million recorded for income tax uncertainties as of September 30, 2014 and December 31, 2013, respectively.  The $1.4 million change in income tax uncertainties is primarily the result of an audit settlement and the lapse in the statute of limitations for certain tax items.  The amount, if recognized, that would impact the effective tax rate is $6.4 and $7.8 million, respectively.  The Company estimates that it is reasonably possible that the liability for uncertain tax positions will decrease by no more than $5 million in the next twelve months from the resolution of various uncertain positions as a result of the completion of tax audits, litigation and the expiration of the statute of limitations in various jurisdictions.

 

NOTE 5 – RETIREMENT AND DEFERRED COMPENSATION PLANS

 

Components of Net Periodic Benefit Cost:

 

 

 

 

Domestic Plans

 

Foreign Plans

 

Three months ended September 30,

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Service cost

 

$

2,011

 

$

2,135

 

$

1,043

 

$

974

 

Interest cost

 

1,482

 

1,248

 

676

 

668

 

Expected return on plan assets

 

(1,647

)

(1,443

)

(494

)

(454

)

Amortization of net loss

 

718

 

1,276

 

303

 

353

 

Amortization of prior service cost

 

--

 

--

 

78

 

93

 

Net periodic benefit cost

 

$

2,564

 

$

3,216

 

$

1,606

 

$

1,634

 

 

 

 

 

 

 

 

 

 

 

 

 

Domestic Plans

 

Foreign Plans

 

Nine months ended September 30,

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Service cost

 

$

6,032

 

$

6,405

 

$

3,203

 

$

2,902

 

Interest cost

 

4,446

 

3,744

 

2,074

 

1,991

 

Expected return on plan assets

 

(4,939

)

(4,331

)

(1,514

)

(1,353

)

Amortization of net loss

 

2,152

 

3,827

 

929

 

1,053

 

Amortization of prior service cost

 

--

 

2

 

239

 

278

 

Net periodic benefit cost

 

$

7,691

 

$

9,647

 

$

4,931

 

$

4,871

 

 

EMPLOYER CONTRIBUTIONS

Although the Company has no minimum funding requirement, the Company contributed $10.0 million to our U.S. plan during the third quarter and the first nine months of 2014 and does not expect to make any contribution to the U.S. plan in the last quarter of 2014.  The Company expects to contribute approximately $5.6 million to our foreign defined benefit plans in 2014 and, as of September 30, 2014, we have contributed approximately $2.0 million.

 

NOTE 6 – ACCUMULATED OTHER COMPREHENSIVE INCOME

 

Changes in Accumulated Other Comprehensive Income by Component:

 

 

 

Foreign
Currency

 

Defined Benefit
Pension Plans

 

Other

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance – December 31, 2012

 

$

120,097

 

$

(59,248

)

$

(166

)

$

60,683

 

Other comprehensive income before reclassifications

 

16,275

 

--

 

--

 

16,275

 

Amounts reclassified from accumulated other comprehensive income

 

--

 

3,294

 

39

 

3,333

 

Net current-period other comprehensive income

 

16,275

 

3,294

 

39

 

19,608

 

Balance – September 30, 2013

 

$

136,372

 

$

(55,954

)

$

(127

)

$

80,291

 

 

 

 

 

 

 

 

 

 

 

Balance – December 31, 2013

 

$

149,965

 

$

(40,093

)

$

(121

)

$

109,751

 

Other comprehensive loss before reclassifications

 

(123,014

)

--

 

--

 

(123,014

)

Amounts reclassified from accumulated other comprehensive income

 

(340

)

2,144

 

18

 

1,822

 

Net current-period other comprehensive (loss) income

 

(123,354

)

2,144

 

18

 

(121,192

)

Balance – September 30, 2014

 

$

26,611

 

$

(37,949

)

$

(103

)

$

(11,441

)

 

9



Table of Contents

 

Reclassifications Out of Accumulated Other Comprehensive Income:

 

Details about Accumulated Other

 

Amount Reclassified from Accumulated

 

Affected Line in the Statement

 

Comprehensive Income Components

 

Other Comprehensive Income

 

Where Net Income is Presented

 

Three months ended September 30,

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Defined Benefit Pension Plans

 

 

 

 

 

 

 

Amortization of net loss

 

$

1,021

 

$

1,629

 

(a)

 

Amortization of prior service cost

 

78

 

93

 

(a)

 

Total before tax

 

1,099

 

1,722

 

 

 

 

 

(390

)

(622

)

Tax benefit

 

Net of tax

 

$

709

 

$

1,100

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

Changes in treasury locks

 

9

 

14

 

Interest Expense

 

Total before tax

 

9

 

14

 

 

 

 

 

(3

)

(5

)

Tax benefit

 

Net of tax

 

$

6

 

$

9

 

 

 

 

 

 

 

 

 

 

 

Total reclassifications for the period

 

$

715

 

$

1,109

 

 

 

 

(a)         These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax (see Note 5 – Retirement and Deferred Compensation Plans for additional details).

 

Details about Accumulated Other

 

Amount Reclassified from Accumulated

 

Affected Line in the Statement

 

Comprehensive Income Components

 

Other Comprehensive Income

 

Where Net Income is Presented

 

Nine months ended September 30,

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Defined Benefit Pension Plans

 

 

 

 

 

 

 

Amortization of net loss

 

$

3,081

 

$

4,880

 

(b)

 

Amortization of prior service cost

 

239

 

280

 

(b)

 

Total before tax

 

3,320

 

5,160

 

 

 

 

 

(1,176

)

(1,866

)

Tax benefit

 

Net of tax

 

$

2,144

 

$

3,294

 

 

 

 

 

 

 

 

 

 

 

Foreign Currency

 

 

 

 

 

 

 

Foreign currency gain

 

(340

)

--

 

Miscellaneous, net

 

Total before tax

 

(340

)

--

 

 

 

 

 

--

 

--

 

Tax benefit

 

Net of tax

 

$

(340

)

$

--

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

Changes in treasury locks

 

28

 

60

 

Interest Expense

 

Total before tax

 

28

 

60

 

 

 

 

 

(10

)

(21

)

Tax benefit

 

Net of tax

 

$

18

 

$

39

 

 

 

 

 

 

 

 

 

 

 

Total reclassifications for the period

 

$

1,822

 

$

3,333

 

 

 

 

(b)         These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax (see Note 5 – Retirement and Deferred Compensation Plans for additional details).

 

10



Table of Contents

 

NOTE 7 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

 

The Company maintains a foreign exchange risk management policy designed to establish a framework to protect the value of the Company’s non-functional denominated transactions from adverse changes in exchange rates.  Sales of the Company’s products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated.  Changes in exchange rates on such inter-country sales or intercompany loans can impact the Company’s results of operations.  The Company’s policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency.  The Company may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

The Company maintains an interest rate risk management strategy to minimize significant, unanticipated earnings fluctuations that may arise from volatility in interest rates.

For derivative instruments designated as hedges, the Company formally documents the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness.  Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur.

 

HEDGE OF NET INVESTMENTS IN FOREIGN OPERATIONS

A significant number of the Company’s operations are located outside of the United States.  Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of the Company’s foreign subsidiaries.  A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on the Company’s financial condition and results of operations.  Conversely, a weakening U.S. dollar has an additive effect.  The Company in some cases maintains debt in these subsidiaries to offset the net asset exposure.  The Company does not otherwise actively manage this risk using derivative financial instruments.  In the event the Company plans on a full or partial liquidation of any of our foreign subsidiaries where the Company’s net investment is likely to be monetized, the Company will consider hedging the currency exposure associated with such a transaction.

 

OTHER

As of September 30, 2014, the Company has recorded the fair value of foreign currency forward exchange contracts of $0.8 million in prepaid and other, $0.1 million in miscellaneous other assets, $3.0 million in accounts payable and accrued liabilities, and $0.3 million in deferred and other non-current liabilities in the balance sheet.  All forward exchange contracts outstanding as of September 30, 2014 had an aggregate contract amount of $155 million.

 

 

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2014

and December 31, 2013

 

Derivative Contracts Not Designated
as Hedging Instruments

 

Balance Sheet
Location

 

September
30, 2014

 

December
31, 2013

 

 

 

 

 

 

 

 

 

Derivative Assets

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

Prepaid and other

 

$

801

 

$

3,003

 

Foreign Exchange Contracts

 

Miscellaneous Other Assets

 

62

 

985

 

 

 

 

 

$

863

 

$

3,988

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

Accounts payable and accrued liabilities

 

$

3,044

 

$

522

 

Foreign Exchange Contracts

 

Deferred and other non-current liabilities

 

345

 

110

 

 

 

 

 

$

3,389

 

$

632

 

 

 

The Effect of Derivative Instruments on the Condensed Consolidated Statements of Income

for the Quarters Ended September 30, 2014 and September 30, 2013

 

Derivatives Not Designated as
Hedging Instruments

 

Location of (Loss) or Gain Recognized in
Income on Derivative

 

Amount of (Loss) or Gain
Recognized in Income on
Derivative

 

 

 

 

 

2014

 

2013

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

Other Income (Expense) Miscellaneous, net

 

$

(1,965

)

$

2,894

 

 

 

 

 

$

(1,965

)

$

2,894

 

 

 

The Effect of Derivative Instruments on the Condensed Consolidated Statements of Income

for the Nine Months Ended September 30, 2014 and September 30, 2013

 

Derivatives Not Designated as
Hedging Instruments

 

Location of (Loss) or Gain Recognized in
Income on Derivative

 

Amount of (Loss) or Gain
Recognized in Income on
Derivative

 

 

 

 

 

2014

 

2013

 

 

 

 

 

 

 

 

 

Foreign Exchange Contracts

 

Other Income (Expense) Miscellaneous, net

 

$

(3,459

)

$

2,851

 

 

 

 

 

$

(3,459

)

$

2,851

 

 

11



Table of Contents

 

 

 

 

 

 

 

 

Net Amounts

 

Gross Amounts not Offset in the

 

 

 

 

 

 

 

Gross Amounts

 

Presented in

 

Statement of Financial Position

 

 

 

 

 

Gross

 

Offset in the

 

the Statement of

 

Financial

 

Cash Collateral

 

Net

 

 

 

Amount

 

Financial Position

 

Financial Position

 

Instruments

 

Received

 

Amount

 

Description

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Assets

 

$

863

 

--

 

$

863

 

--

 

--

 

$

863

 

Total Assets

 

$

863

 

--

 

$

863

 

--

 

--

 

$

863

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

$

3,389

 

--

 

$

3,389

 

--

 

--

 

$

3,389

 

Total Liabilities

 

$

3,389

 

--

 

$

3,389

 

--

 

--

 

$

3,389

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2013

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Assets

 

$

3,988

 

--

 

$

3,988

 

--

 

--

 

$

3,988

 

Total Assets

 

$

3,988

 

--

 

$

3,988

 

--

 

--

 

$

3,988

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

$

632

 

--

 

$

632

 

--

 

--

 

$

632

 

Total Liabilities

 

$

632

 

--

 

$

632

 

--

 

--

 

$

632

 

 

NOTE 8 – FAIR VALUE

 

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities.  Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.  The three levels are defined as follows:

·                  Level 1:  Unadjusted quoted prices in active markets for identical assets and liabilities.

·                  Level 2:  Observable inputs other than those included in Level 1.  For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

·                  Level 3:  Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

 

As of September 30, 2014, the fair values of our financial assets and liabilities were categorized as follows:

 

 

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

Forward exchange contracts (a)

 

$

863

 

$

--

 

$

863

 

$

--

 

Total assets at fair value

 

$

863

 

$

--

 

$

863

 

$

--

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Forward exchange contracts (a)

 

$

3,389

 

$

--

 

$

3,389

 

$

--

 

Total liabilities at fair value

 

$

3,389

 

$

--

 

$

3,389

 

$

--

 

 

As of December 31, 2013, the fair values of our financial assets and liabilities were categorized as follows:

 

 

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Assets

 

 

 

 

 

 

 

 

 

Forward exchange contracts (a)

 

$

3,988

 

$

--

 

$

3,988

 

$

--

 

Total assets at fair value

 

$

3,988

 

$

--

 

$

3,988

 

$

--

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Forward exchange contracts (a)

 

$

632

 

$

--

 

$

632

 

$

--

 

Total liabilities at fair value

 

$

632

 

$

--

 

$

632

 

$

--

 

 

(a)   Market approach valuation technique based on observable market transactions of spot and forward rates

 

The carrying amounts of the Company’s other current financial instruments such as cash and equivalents, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument.  The Company considers our long-term obligations a Level 2 liability and utilizes the market approach valuation technique based on interest rates that are currently available to the Company for issuance of debt with similar terms and maturities.  The estimated fair value of the Company’s long-term obligations was $370 million as of September 30, 2014 and $363 million as of December 31, 2013.

 

12



Table of Contents

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature.  While management believes the resolution of these claims and lawsuits will not have a material adverse effect on the Company’s financial position or results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established.  Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

 

NOTE 10 – STOCK REPURCHASE PROGRAM

 

During the three and nine months ended September 30, 2014, the Company repurchased approximately 600 thousand and 1.4 million shares for approximately $37.6 million and $90.5 million, respectively.  As of September 30, 2014, the Company has a remaining authorization to repurchase 2.6 million additional shares.  The timing of and total amount expended for the share repurchases depends upon market conditions.  On October 30, 2014, the Company announced a new share repurchase authorization of up to $350 million of common stock.  This new authorization replaces previous authorizations.  AptarGroup may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

 

NOTE 11 – STOCK-BASED COMPENSATION

 

The Company issues stock options and restricted stock units to employees under Stock Awards Plans approved by stockholders.  Stock options are issued to non-employee directors under Director Stock Option Plans approved by stockholders. Options are awarded with the exercise price equal to the closing market price on the date of grant and generally become exercisable over three years and expire 10 years after grant.  Restricted stock units generally vest over three years.

Compensation expense recorded attributable to stock options for the first nine months of 2014 was approximately $15.0 million ($9.8 million after tax).  The income tax benefit related to this compensation expense was approximately $5.2 million.  Approximately $13.4 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales.  Compensation expense recorded attributable to stock options for the first nine months of 2013 was approximately $11.5 million ($7.7 million after tax).  The income tax benefit related to this compensation expense was approximately $3.8 million.  Approximately $10.2 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales.

The Company uses historical data to estimate expected life and volatility of stock options.  The weighted-average fair value of stock options granted under the Stock Awards Plans was $14.82 and $10.16 per share during the first nine months of 2014 and 2013, respectively.  These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

 

 

Stock Awards Plans:

 

 

 

 

 

Nine months ended September 30,

 

2014

 

2013

 

 

 

 

 

 

 

Dividend Yield

 

1.7

%

1.8

%

Expected Stock Price Volatility

 

22.1

%

22.7

%

Risk-free Interest Rate

 

2.3

%

1.3

%

Expected Life of Option (years)

 

6.9

 

6.9

 

 

The fair value of stock options granted under the Director Stock Option Plan was $14.07 and $10.89 per share during the first nine months of 2014 and 2013, respectively.  These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

 

 

Director Stock Option Plans:

 

 

 

 

 

Nine months ended September 30,

 

2014

 

2013

 

 

 

 

 

 

 

Dividend Yield

 

1.8

%

1.9

%

Expected Stock Price Volatility

 

22.2

%

23.0

%

Risk-free Interest Rate

 

2.2

%

1.3

%

Expected Life of Option (years)

 

6.9

 

6.9

 

 

A summary of option activity under the Company’s stock option plans during the nine months ended September 30, 2014 is presented below:

 

13



Table of Contents

 

 

 

 

Stock Awards Plans

 

Director Stock Option Plans

 

 

 

 

 

Weighted Average

 

 

 

Weighted Average

 

 

 

Shares

 

Exercise Price

 

Shares

 

Exercise Price

 

 

 

 

 

 

 

 

 

 

 

Outstanding, January 1, 2014

 

7,815,932

 

$

41.26

 

313,834

 

$

48.85

 

Granted

 

1,379,850

 

67.93

 

95,000

 

66.59

 

Exercised

 

(665,671

)

32.23

 

(40,166

)

47.96

 

Forfeited or expired

 

(31,417

)

49.86

 

--

 

--

 

Outstanding at September 30, 2014

 

8,498,694

 

$

46.27

 

368,668

 

$

53.52

 

Exercisable at September 30, 2014

 

5,832,623

 

$

39.94

 

188,159

 

$

45.98

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average Remaining Contractual Term (Years):

 

 

 

 

 

 

 

Outstanding at September 30, 2014

 

6.1

 

 

 

7.5

 

 

 

Exercisable at September 30, 2014

 

5.0

 

 

 

6.1

 

 

 

 

 

 

 

 

 

 

 

 

 

Aggregate Intrinsic Value:

 

 

 

 

 

 

 

 

 

Outstanding at September 30, 2014

 

$

132,612

 

 

 

$

3,208

 

 

 

Exercisable at September 30, 2014

 

$

121,124

 

 

 

$

2,769

 

 

 

 

 

 

 

 

 

 

 

 

 

Intrinsic Value of Options Exercised During the Nine Months Ended:

 

 

 

 

 

September 30, 2014

 

$

22,386

 

 

 

$

741

 

 

 

September 30, 2013

 

$

33,123

 

 

 

$

732

 

 

 

 

The fair value of options vested during the nine months ended September 30, 2014 and 2013 was $14.1 million and $12.9 million, respectively.  Cash received from option exercises was approximately $24.6 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $7.0 million in the nine months ended September 30, 2014.  As of September 30, 2014, the remaining valuation of stock option awards to be expensed in future periods was $16.1 million and the related weighted-average period over which it is expected to be recognized is 1.5 years.

The fair value of restricted stock unit grants is the closing market price of the underlying shares on the grant date.  A summary of restricted stock unit activity during the nine months ended September 30, 2014 is presented below:

 

 

 

 

 

 

Weighted-Average

 

 

 

Shares

 

Grant-Date Fair Value

 

 

 

 

 

 

 

Nonvested at January 1, 2014

 

25,681

 

$

53.49

 

Granted

 

47,671

 

67.08

 

Vested

 

(11,602

)

52.96

 

Nonvested at September 30, 2014

 

61,750

 

$

64.09

 

 

Compensation expense recorded attributable to restricted stock unit grants for the first nine months of 2014 and 2013 was approximately $1.4 million and $574 thousand, respectively.  The fair value of units vested during the nine months ended September 30, 2014 and 2013 was $614 thousand and $571 thousand, respectively.  The intrinsic value of units vested during the nine months ended September 30, 2014 and 2013 was $761 thousand and $661 thousand, respectively.  As of September 30, 2014 there was $2.3 million of total unrecognized compensation expense relating to restricted stock unit awards which is expected to be recognized over a weighted-average period of 1.6 years.

During the first quarter of 2014, the Company approved a new long-term incentive program for certain employees.  The program is based on the cumulative total stockholder return of our common stock during a three year performance period.  Total expense related to this program is expected to be approximately $1.2 million over the performance period, of which $480 thousand was recognized in the first nine months of 2014.

 

NOTE 12 – EARNINGS PER SHARE

 

AptarGroup’s authorized common stock consists of 199 million shares, having a par value of $.01 each.  Information related to the calculation of earnings per share is as follows:

 

 

 

 

Three months ended

 

 

 

September 30, 2014

 

September 30, 2013

 

 

 

Diluted

 

Basic

 

Diluted

 

Basic

 

Consolidated operations

 

 

 

 

 

 

 

 

 

Income available to common stockholders

 

$

48,595

 

$

48,595

 

$

45,264

 

$

45,264

 

 

 

 

 

 

 

 

 

 

 

Average equivalent shares

 

 

 

 

 

 

 

 

 

Shares of common stock

 

64,886

 

64,886

 

66,092

 

66,092

 

Effect of dilutive stock based compensation

 

 

 

 

 

 

 

 

 

Stock options

 

1,953

 

--

 

1,887

 

--

 

Restricted stock units

 

6

 

--

 

7

 

--

 

Total average equivalent shares

 

66,845

 

64,886

 

67,986

 

66,092

 

Net income per share

 

$

0.73

 

$

0.75

 

$

0.67

 

$

0.68

 

 

14



Table of Contents

 

 

 

Nine months ended

 

 

 

September 30, 2014

 

September 30, 2013

 

 

 

Diluted

 

Basic

 

Diluted

 

Basic

 

Consolidated operations

 

 

 

 

 

 

 

 

 

Income available to common stockholders

 

$

150,060

 

$

150,060

 

$

135,095

 

$

135,095

 

 

 

 

 

 

 

 

 

 

 

Average equivalent shares

 

 

 

 

 

 

 

 

 

Shares of common stock

 

65,225

 

65,225

 

66,222

 

66,222

 

Effect of dilutive stock based compensation

 

 

 

 

 

 

 

 

 

Stock options

 

2,505

 

--

 

2,041

 

--

 

Restricted stock units

 

31

 

--

 

10

 

--

 

Total average equivalent shares

 

67,761

 

65,225

 

68,273

 

66,222

 

Net income per share

 

$

2.21

 

$

2.30

 

$

1.98

 

$

2.04

 

 

NOTE 13 – SEGMENT INFORMATION

 

The Company operates in the packaging components industry, which includes the development, manufacture and sale of consumer product dispensing solutions.  The Company is organized into three reporting segments.  Operations that sell dispensing systems primarily to the personal care, beauty and home care markets form the Beauty + Home segment.  Operations that sell dispensing systems primarily to the prescription drug, consumer health care and injectables markets form the Pharma segment.  Operations that sell dispensing systems primarily to the food and beverage markets form the Food + Beverage segment.

The accounting policies of the segments are the same as those described in Note 1, Summary of Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.  Segment income is defined as earnings before net interest expense, certain corporate expenses, restructuring initiatives and related depreciation and income taxes.

 

Financial information regarding the Company’s reportable segments is shown below:

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Total Revenue:

 

 

 

 

 

 

 

 

 

Beauty + Home

 

$

384,604

 

$

379,250

 

$

1,174,359

 

$

1,125,261

 

Pharma

 

179,191

 

172,360

 

569,230

 

524,248

 

Food + Beverage

 

94,118

 

75,531

 

274,936

 

244,434

 

Total Revenue

 

657,913

 

627,141

 

2,018,525

 

1,893,943

 

 

 

 

 

 

 

 

 

 

 

Less: Intersegment Sales:

 

 

 

 

 

 

 

 

 

Beauty + Home

 

$

5,699

 

$

3,199

 

$

18,992

 

$

10,754

 

Pharma

 

--

 

90

 

--

 

178

 

Food + Beverage

 

272

 

208

 

909

 

293

 

Total Intersegment Sales

 

$

5,971

 

$

3,497

 

$

19,901

 

$

11,225

 

 

 

 

 

 

 

 

 

 

 

Net Sales:

 

 

 

 

 

 

 

 

 

Beauty + Home

 

$

378,905

 

$

376,051

 

$

1,155,367

 

$

1,114,507

 

Pharma

 

179,191

 

172,270

 

569,230

 

524,070

 

Food + Beverage

 

93,846

 

75,323

 

274,027

 

244,141

 

Net Sales

 

$

651,942

 

$

623,644

 

$

1,998,624

 

$

1,882,718

 

 

 

 

 

 

 

 

 

 

 

Segment Income:

 

 

 

 

 

 

 

 

 

Beauty + Home

 

$

25,399

 

$

30,943

 

$

80,378

 

$

85,697

 

Pharma

 

49,314

 

44,737

 

154,589

 

141,154

 

Food + Beverage

 

11,713

 

7,688

 

33,209

 

28,102

 

Restructuring Initiatives and

 

 

 

 

 

 

 

 

 

Related Depreciation (1)

 

--

 

(2,664

)

--

 

(10,257

)

Corporate & Other

 

(8,364

)

(8,113

)

(28,664

)

(27,605

)

Income before interest and taxes

 

$

78,062

 

$

72,591

 

$

239,512

 

$

217,091

 

Interest expense, net

 

(3,946

)

(4,265

)

(12,010

)

(13,093

)

Income before income taxes

 

$

74,116

 

$

68,326

 

$

227,502

 

$

203,998

 

 

(1)                                 Restructuring Initiatives and Related Depreciation includes the following income/(expense) items for the three and nine months ended September 30, 2014:

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

European Restructuring Plan

 

 

 

 

 

 

 

 

 

Depreciation

 

$

--

 

$

484

 

$

--

 

$

1,499

 

Employee Severance and Other Costs

 

--

 

2,180

 

--

 

8,802

 

Prior Year Initiatives

 

--

 

--

 

--

 

(44

)

Total Restructuring Initiatives and Related Depreciation Expense

 

$

--

 

$

2,664

 

$

--

 

$

10,257

 

 

 

 

 

 

 

 

 

 

 

Restructuring Initiatives and Related Depreciation Expense by Segment

 

 

 

 

 

Beauty + Home

 

$

--

 

$

2,664

 

$

--

 

$

10,280

 

Pharma

 

--

 

--

 

--

 

--

 

Food + Beverage

 

--

 

--

 

--

 

(23

)

Total Restructuring Initiatives and Related Depreciation Expense

 

$

--

 

$

2,664

 

$

--

 

$

10,257

 

 

15



Table of Contents

 

NOTE 14 – NONRECURRING EVENTS

 

A fire caused damages to the roof and production area of an AptarGroup subsidiary, Graphocolor do Brasil Embalagens Ltda, on September 1, 2014.  Graphocolor is located in Jundiai, Brazil.  There were no reported injuries.  Graphocolor is primarily an internal supplier to AptarGroup of anodized aluminum components for certain dispensing systems sold to the regional beauty and personal care markets.  Until repairs to the Jundiai facility are completed, the company is using sourcing alternatives, including local sourcing and its affiliated anodizing facilities in France and the U.S. that currently import some components to the region.  AptarGroup is insured for the damages caused by the fire, including business interruption insurance, and it does not expect this incident to have a material impact on its financial results.  Costs, including the write-off of damaged fixed assets and inventory along with labor and other direct costs related to fire, of $3.7 million were incurred during the quarter.  These costs have been reported within the Condensed Consolidated Statements of Income and have been offset by the expected insurance proceeds within the same financial statement line items as the losses.

As we are still in the investigation phase, we have only established an insurance receivable for known losses for which we feel insurance reimbursement is probable.  In many cases, our insurance coverage exceeds the amount of these covered losses, but no gain contingencies have been recognized as our ability to realize those gains remains uncertain for financial reporting purposes.

 

NOTE 15 - ACQUISITIONS

 

In December 2013, AptarGroup acquired a 20% non-controlling investment in Bapco Closures Holding Limited (Bapco) for approximately $5.2 million.  In addition to this equity stake, the Company secured an exclusive global license related to innovative closures sealing technology that provides package integrity and tamper evidence.  This investment is being accounted for under the equity method of accounting from the date of acquisition and, since it does not have a material impact on the results of operations in 2014 or 2013, pro forma information is not presented.

 

NOTE 16 – RESTRUCTURING INITIATIVE

 

In November 2012, the Company announced a plan to optimize certain capacity in Europe.  Due to increased production efficiencies and to better position the Company for future growth in Europe, AptarGroup transferred and consolidated production capacity involving twelve facilities.  Two facilities have closed impacting approximately 170 employees.  The locations involved in the plan are facilities serving the beauty, personal care, food, beverage, and consumer health care markets.  As of December 31, 2013, the plan was substantially complete.  The cumulative expense incurred was $19.5 million.  As of September 30, 2014 we have recorded the following activity associated with our European restructuring plan:

 

 

 

Beginning

 

Net Charges for

 

 

 

 

 

Ending

 

 

 

Reserve at

 

the Nine Months

 

 

 

 

 

Reserve at

 

 

 

12/31/13

 

Ended 9/30/14

 

Cash Paid

 

FX Impact

 

9/30/14

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee severance

 

$

2,521

 

$

--

 

$

(1,933

)

$

(158

)

$

430

 

Other costs

 

1,735

 

--

 

(1,568

)

(82

)

85

 

Totals

 

$

4,256

 

$

--

 

$

(3,501

)

$

(240

)

$

515

 

 

16



Table of Contents

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)

 

RESULTS OF OPERATIONS

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

100.0

%

100.0

%

100.0

%

100.0

%

Cost of sales (exclusive of depreciation and amortization shown below)

 

68.0

 

68.0

 

67.4

 

67.7

 

Selling, research & development and administrative

 

14.1

 

13.9

 

14.8

 

14.3

 

Depreciation and amortization

 

5.8

 

6.0

 

5.7

 

5.9

 

Restructuring initiatives

 

--

 

0.3

 

--

 

0.5

 

Operating Income

 

12.1

 

11.8

 

12.1

 

11.6

 

Other expense

 

(0.7

)

(0.8

)

(0.7

)

(0.8

)

Income before Income Taxes

 

11.4

 

11.0

 

11.4

 

10.8

 

 

 

 

 

 

 

 

 

 

 

Net income

 

7.5

%

7.3

%

7.5

%

7.2

%

 

 

 

 

 

 

 

 

 

 

Effective Tax Rate

 

34.4

%

33.8

%

34.0

%

33.8

%

 

NET SALES

 

We reported net sales of $651.9 million for the quarter ended September 30, 2014, 5% above third quarter 2013 reported net sales of $623.6 million.  The average U.S. dollar exchange rate strengthened slightly relative to the Euro in the third quarter of 2014 compared to the third quarter of 2013.  The U.S. dollar also strengthened against the Argentine Peso and Chinese Yuan but weakened against the British Pound and Brazilian Real.  As a result, net changes in exchange rates unfavorably impacted our total consolidated reported sales growth by 1%.  Therefore, sales excluding changes in foreign currency rates increased by 6% in the third quarter of 2014 compared to the third quarter of 2013.  Each business segment reported an increase in sales:

 

Third Quarter 2014

 

Beauty

 

 

 

Food +

 

 

 

Net Sales Change over Prior Year

 

+ Home

 

Pharma

 

Beverage

 

Total

 

 

 

 

 

 

 

 

 

 

 

Product Sales (including tooling)

 

2

%

5

%

25

%

6

%

Currency Effects

 

(1

%)

(1

%)

--

 

(1

%)

Total Reported Net Sales Growth

 

1

%

4

%

25

%

5

%

 

For the first nine months of 2014, we reported net sales of $2.00 billion, 6% above the first nine months of 2013 reported net sales of $1.88 billion.  The average U.S. dollar exchange rate weakened relative to the Euro in 2014 compared to 2013.  However, the U.S. dollar strengthened compared to other foreign currencies, such as the Brazilian Real, Argentine Peso, Indian Rupee and Russian Ruble.  Therefore, total consolidated sales for the first nine months of 2014 were not impacted by changes in foreign currency rates when compared to first nine months of 2013:

 

First Nine Months of 2014

 

Beauty

 

 

 

Food +

 

 

 

Net Sales Change over Prior Year

 

+ Home

 

Pharma

 

Beverage

 

Total

 

 

 

 

 

 

 

 

 

 

 

Product Sales (including tooling)

 

4

%

7

%

12

%

6

%

Currency Effects

 

--

 

2

%

--

 

--

 

Total Reported Net Sales Growth

 

4

%

9

%

12

%

6

%

 

For further discussion on net sales by reporting segment, please refer to the segment analysis of net sales and segment income on the following pages.

 

The following table sets forth, for the periods indicated, net sales by geographic location:

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

% of Total

 

2013

 

% of Total

 

2014

 

% of Total

 

2013

 

% of Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

 

$

157,157

 

24

%

$

152,213

 

25

%

$

489,328

 

24

%

$

478,686

 

26

%

Europe

 

362,560

 

56

%

357,891

 

57

%

1,155,301

 

58

%

1,076,695

 

57

%

Other Foreign

 

132,225

 

20

%

113,540

 

18

%

353,995

 

18

%

327,337

 

17

%

 

 

$

651,942

 

 

 

$

623,644

 

 

 

$

1,998,624

 

 

 

$

1,882,718

 

 

 

 

17



Table of Contents

 

COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)

 

Our cost of sales as a percent of net sales was 68.0% in both the third quarter of 2014 and the third quarter of 2013.  The negative impacts of operational inefficiencies in our Beauty + Home segment’s North American operations along with startup costs for our new facility in Colombia were offset by the approximately $1.3 million of incremental cost savings from our European restructuring plan.

In the first nine months of 2014, cost of sales as a percent of net sales decreased slightly to 67.4% compared to 67.7% in the same period a year ago.  This decrease mainly relates to approximately $5.0 million of incremental cost savings from our European restructuring plan partially offset by the negative impacts of operational inefficiencies in our Beauty + Home segment’s North American operations along with currency effects and startup costs for our new facility in Colombia.

 

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

 

Our Selling, Research & Development and Administrative expenses (“SG&A”) increased by approximately $4.7 million in the third quarter of 2014 compared to the same period a year ago.  Excluding changes in foreign currency rates, SG&A increased by approximately $4.9 million in the quarter.  The increase is due to several factors, including higher research and development costs associated with our recently acquired bonded aluminum to plastic license along with higher information technology costs associated with our ongoing enterprise resource planning system roll-ins.  SG&A as a percentage of net sales increased to 14.1% compared to 13.9% in the same period of the prior year due primarily to the increase in expenses noted above.

SG&A increased by approximately $25.5 million in the first nine months of 2014 compared to the same period a year ago.  Excluding changes in foreign currency rates, SG&A increased by approximately $24.0 million in the first nine months of the year.  As discussed above, the increase is mainly due to our investments in research and development and information technology systems along with higher stock compensation expense.  SG&A as a percentage of net sales increased to 14.8% in the first nine months of 2014 compared to 14.3% in the first nine months of 2013 primarily due to higher expenses during the current year.

 

DEPRECIATION AND AMORTIZATION

 

Reported depreciation and amortization expenses increased by approximately $0.9 million in the third quarter of 2014 compared to the same period a year ago.  Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $1.1 million in the quarter compared to the same period a year ago.  Investments in our new products and the continued roll-out of our global enterprise resource planning system were partially offset by an additional $0.5 million of accelerated depreciation related to our European restructuring initiatives during 2013.  Depreciation and amortization as a percentage of net sales slightly decreased to 5.8% in the third quarter of 2014 compared to 6.0% in the same period a year ago mainly due to our increase in sales during the third quarter of 2014.

For the first nine months of 2014, reported depreciation and amortization expenses increased by approximately $1.9 million compared to the first nine months of 2013.  Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $0.9 million in the first nine months.  The investments in our new products and the continued roll-out of our global enterprise resource planning system mentioned above offset 2013 one-time charges of $1.5 million for accelerated depreciation on certain corporate assets and $1.5 million for accelerated depreciation related to our restructuring.  Depreciation and amortization as a percentage of net sales decreased to 5.7% compared to 5.9% for the same period a year ago.

 

RESTRUCTURING INITIATIVES

 

In November 2012, the Company announced a plan to optimize certain capacity in Europe.  Due to increased production efficiencies and to better position the Company for future growth in Europe, AptarGroup transferred and consolidated production capacity involving twelve facilities.  Under the plan, two facilities were closed impacting approximately 170 employees.  During the three and nine months ended September 30, 2013, we recognized $2.2 million and $8.8 million of restructuring expenses, respectively, along with the $0.5 million and $1.5 million of accelerated depreciation of assets, respectively, mentioned above.  The plan was substantially completed at the end of 2013 with total costs of approximately $19.5 million.  Savings from the plan are expected to be approximately $10 million on an annualized basis.

 

OPERATING INCOME

 

Operating income increased approximately $5.3 million in the third quarter of 2014 to $78.6 million compared to $73.3 million in the same period in the prior year.  Excluding changes in currency rates, operating income increased by approximately $5.9 million in the quarter.  2013 results included the negative impact of the European restructuring plan charges of $2.2 million.  The remaining $3.7 million increase in operating income over the prior year is due to our sales growth, primarily from the Food + Beverage segment.  Reported operating income as a percentage of net sales increased to 12.1% in the third quarter of 2014 compared to 11.8% for the same period in the prior year due to the European restructuring plan charges in 2013.

Operating income increased approximately $23.2 million in the first nine months of 2014 to $242.0 million compared to $218.8 million in the same period in the prior year.  Excluding changes in currency rates, operating income increased by approximately $20.0 million in the first nine months of 2014.  2013 results included the negative impact of the European restructuring plan charges of $9.1 million.  The remaining $10.9 million increase in operating income over the prior year is again due to our sales growth, primarily from the Food + Beverage segment.  Consistent with the third quarter results, reported

 

18



Table of Contents

 

operating income as a percentage of net sales increased to 12.1% in the first nine months of 2014 compared to 11.6% for the same period in the prior year due to the European restructuring plan charges in 2013.

 

NET OTHER EXPENSE

 

Net other expenses in the third quarter of 2014 decreased to $4.5 million from $5.0 million in the same period in the prior year.  This decrease is mainly due to higher interest income resulting from higher invested cash balances in Europe related to the tax decision not to repatriate funds to the U.S. in 2014.

Net other expenses for the nine months ended September 30, 2014 decreased slightly to $14.5 million from $14.8 million in the same period in the prior year.  Higher interest income and lower hedging costs were mostly offset by the recognition of a $1.5 million write-down on a non-controlling investment taken during the first quarter of 2014 to align with the current fair value.

 

EFFECTIVE TAX RATE

 

The reported effective tax rate was 34.4% for the three months ended September 30, 2014 compared to 33.8% for the same period ended September 30, 2013.  The increase in the rate for the three months ended September 30, 2014 reflects costs related to a non-U.S. subsidiary legal reorganization.  These additional costs were mostly offset by increased foreign tax credits available as a result of the currency devaluation in Latin America.

The reported effective tax rate was 34.0% for the nine months ended September 30, 2014 compared to 33.8% for the same period ended September 30, 2013.  The slight increase in the rate for the nine months ended September 30, 2014 was mainly due to the same items as discussed above.  Additionally, although the effective tax rate increased in 2014 due to tax law changes enacted in France in December 2013, the increase was offset by our decision not to repatriate funds from Europe in 2014 and the absence of any associated tax costs.

 

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

 

We reported net income attributable to AptarGroup, Inc. of $48.6 million and $150.1 million in the three and nine months ended September 30, 2014, respectively, compared to $45.3 million and $135.1 million for the same periods in the prior year.

 

BEAUTY + HOME SEGMENT

 

Operations that sell dispensing systems primarily to the personal care, beauty and home care markets form the Beauty + Home segment.

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

378,905

 

$

376,051

 

$

1,155,367

 

$

1,114,507

 

Segment Income

 

25,399

 

30,943

 

80,378

 

85,697

 

Segment Income as a percentage of Net Sales

 

6.7

%

8.2

%

7.0

%

7.7

%

 

Net sales for the Beauty + Home segment increased 1% in the third quarter of 2014 to $378.9 million compared to $376.1 million in the third quarter of 2013.  Sales, excluding changes in foreign currency rates, increased 2%.  Sales, excluding foreign currency changes, to the beauty market increased 5% primarily on the growth of our prestige fragrance products while sales to the personal care market decreased 1% and sales to the home care market increased 3% in the third quarter of 2014 compared to the same period in the prior year.  Geographically, sales increases in Europe, Asia and Latin America offset continued softness in the North American region. Customer tooling sales, excluding foreign currency changes, decreased $2.3 million in the third quarter of 2014 to $6.7 million compared to $9.0 million in the third quarter of the prior year.  Increases in resin pass-throughs to our customers positively impacted sales by $0.4 million.

Net sales for the first nine months of 2014 increased 4% to $1.2 billion compared to $1.1 billion in the first nine months of 2013. Changes in foreign currency rates did not have a material impact on reported sales for the first nine months of 2014.  Sales of our products, excluding foreign currency changes, to the beauty market increased 6% while sales to the personal care and home care markets increased 3% and 7%, respectively, in the first nine months of 2014 compared to the first nine months of 2013.  The increase in beauty sales is primarily due to growth of our prestige fragrance and skin care products.  Customer tooling sales, excluding foreign currency changes, decreased slightly in the first nine months of 2014 to $23.0 million compared to $23.2 million in the first nine months of the prior year.

Segment income for the third quarter of 2014 decreased approximately 18% to $25.4 million compared to $30.9 million reported in the prior year.  The negative impacts of operational inefficiencies in our North American operations along with startup costs for our new facility in Colombia were offset by the approximately $1.3 million of incremental costs savings from our European restructuring plan.

Segment income in the first nine months of 2014 decreased approximately 6% to $80.4 million compared to $85.7 million reported in the same period in the prior year.  Increases in product sales and $5.0 million of savings related to our European restructuring initiative were offset by approximately $2.9 million of negative currency transaction effects and $3.1 million of start-up costs for our new facilities in Latin America along with the operational inefficiencies in North America mentioned above.

 

19



Table of Contents

 

PHARMA SEGMENT

 

Operations that sell dispensing systems to the prescription drug, consumer health care and injectables markets form the Pharma segment.

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

179,191

 

$

172,270

 

$

569,230

 

$

524,070

 

Segment Income

 

49,314

 

44,737

 

154,589

 

141,154

 

Segment Income as a percentage of Net Sales

 

27.5

%

26.0

%

27.2

%

26.9

%

 

Net sales for the Pharma segment increased by 4% in the third quarter of 2014 to $179.2 million compared to $172.3 million in the third quarter of 2013.  Sales, excluding changes in foreign currency rates, increased 5%.  Sales, excluding foreign currency changes, to the prescription and consumer health care markets increased 7% and 8%, respectively.  Prescription increases over the prior year period were mainly due to strong demand for our pain management products while consumer health care’s growth was related to several new eye care product introductions using our ophthalmic squeeze dispenser along with strong cough and cold product sales. Sales, excluding foreign currency changes, to the injectables market decreased 5% due to inventory destocking at certain customers and challenging comparisons to strong sales levels in the third quarter of 2013.

Net sales for the first nine months of 2014 increased by 9% to $569.2 million compared to $524.1 million in the first nine months of the prior year.  Foreign currency changes had a positive impact of 2% on total segment sales.  Excluding changes in foreign currency rates, sales increased by 7% in the first nine months of 2014 compared to the first nine months of 2013.  Excluding foreign currency rate changes, sales to the prescription and consumer health care markets increased 6% and 15%, respectively, in the first nine months of 2014 compared to the same period in the prior year.  Prescription growth was led by strong sales of our products to the asthma/COPD and pain markets while consumer health care increases were due to several new eye care product introductions using our ophthalmic squeeze dispenser along with strong nasal decongestant product sales.  Excluding foreign currency rate changes, sales to the injectables market decreased 1% due to the strong comparable sales volumes in the first nine months of 2013 mentioned above as well as customer overstocking issues.

Segment income in the third quarter of 2014 increased approximately 10% to $49.3 million compared to $44.7 million reported in the same period in the prior year.  This increase is mainly attributed to higher sales for both the prescription and consumer health care markets as mentioned above.

Segment income in the first nine months of 2014 increased approximately 10% to $154.6 million compared to $141.2 million reported in the same period of the prior year.  This increase is again mainly attributed to higher sales for the prescription and consumer health care markets.  The Pharma segment also recognized a $1.5 million expense in the first quarter of 2014 related to the write-down of a non-controlling investment to align with the current fair value.

 

FOOD + BEVERAGE SEGMENT

 

Operations that sell dispensing systems primarily to the food and beverage markets form the Food + Beverage segment.

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

93,846

 

$

75,323

 

$

274,027

 

$

244,141

 

Segment Income

 

11,713

 

7,688

 

33,209

 

28,102

 

Segment Income as a percentage of Net Sales

 

12.5

%

10.2

%

12.1

%

11.5

%

 

Net sales for the Food + Beverage segment increased 25% in the third quarter of 2014 to $93.8 million compared to $75.3 million in the third quarter of 2013.  Changes in foreign currency rates did not have a material impact on reported sales for the quarter. Excluding foreign currency changes, sales to the food market increased 13% while sales to the beverage market increased 42%.  The food market increase is due to improved sales of our products to the sauces/condiments and the dairy creamer markets while the beverage market increase is mainly due to the continued success of our products used on functional beverages in the Asian region as well as increases in custom tooling project sales.  Increases in resin pass-throughs to our customers positively impacted sales by $0.8 million.

Net sales for the first nine months of 2014 increased 12% to $274.0 million compared to $244.1 million in the first nine months of the prior year.  Changes in foreign currency rates did not have a material impact on reported sales for the first nine months of 2014. Excluding foreign currency changes, sales to the food market increased 7% and sales to the beverage market increased 19% in the first nine months of 2014 compared to the same period in the prior year.  Consistent with the third quarter, the nine month food sales increase is mainly due to improving sales of our products to the sauces/condiments and the dairy creamer markets.  The beverage sales increase is driven by the continued success of our products used on functional beverages in the Asian region as well as growth in the concentrate flavoring market in Europe.

Segment income in the third quarter of 2014 increased 52% to $11.7 million compared to $7.7 million during the same period in the prior year.  The impact from the sales increases discussed above was partially offset by higher research and development costs to support ongoing product development initiatives.

Segment income in the first nine months of 2014 increased 18% to $33.2 million compared to $28.1 million reported in the same period of the prior year.  Strong growth in product sales along with improved manufacturing productivity and cost

 

20



Table of Contents

 

absorption offset increased research and development costs and contributed to the improvement in the first nine months of 2014 compared to the same period in the prior year.

 

CORPORATE & OTHER

 

In addition to our three operating business segments, AptarGroup assigns certain costs to “Corporate & Other,” which is presented separately in Note 13 of the Unaudited Notes to the Condensed Consolidated Financial Statements.  Corporate & Other primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our operating segments.  Corporate & Other expense increased slightly to $8.4 million for the quarter ended September 30, 2014 compared to $8.1 million in the third quarter of the prior year mainly due to higher professional fees associated with our legal entity reorganization project in 2014.

Corporate & Other expense in the first nine months of 2014 increased to $28.7 million compared to $27.6 million reported in the same period of the prior year.  The increase is mainly due to increases in professional fees mentioned above.  These increases were partially offset by a $1.5 million adjustment for accelerated depreciation recognized on certain corporate assets in 2013.

 

FOREIGN CURRENCY

 

A significant number of our operations are located outside of the United States.  Because of this, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign entities.  Our primary foreign exchange exposure is to the Euro, but we also have foreign exchange exposure to the Brazilian Real, British Pound and Swiss Franc, among others.  Recently we have experienced volatility in certain currencies, including the Argentine Peso, Brazilian Real, Indian Rupee and the Russian Ruble.  We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain transactions and firm purchase and sales commitments denominated in foreign currencies.  A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements.  Conversely, a weakening U.S. dollar has an additive effect.  In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred.  Changes in exchange rates on such inter-country sales could materially impact our results of operations.

 

QUARTERLY TRENDS

 

Our results of operations in the second half of the year typically are negatively impacted by customer plant shutdowns in the summer months in Europe and plant shutdowns in December.  In the future, our results of operations in a quarterly period could be impacted by factors such as changes in product mix, changes in material costs, changes in growth rates in the industries to which our products are sold, recognition of equity based compensation expense for retirement eligible employees in the period of grant and changes in general economic conditions in any of the countries in which we do business.

We generally incur higher stock option expense in the first quarter compared with the rest of the fiscal year.  Our estimated stock option expense on a pre-tax basis (in $ millions) for the year 2014 compared to 2013 is as follows:

 

 

 

2014

 

2013

 

First Quarter

 

$

8.4

 

$

6.5

 

Second Quarter

 

3.7

 

2.8

 

Third Quarter

 

3.0

 

2.2

 

Fourth Quarter (estimated for 2014)

 

2.9

 

2.2

 

 

 

$

18.0

 

$

13.7

 

 

LIQUIDITY AND CAPITAL RESOURCES

 

Our primary sources of liquidity are cash flow from operations and our revolving credit facility.  In the first nine months of 2014, our operations provided approximately $200.0 million in cash flow compared to $194.5 million for the same period a year ago.  A majority of the operating cash flows were utilized to finance capital expenditures.

We used $127.3 million in cash for investing activities during the first nine months of 2014, compared to $108.3 million during the same period a year ago.  The increase in cash used for investing activities is due primarily to the increase in capital expenditures of $15.1 million in the first nine months of 2014 compared to the first nine months of 2013.  Cash outlays for capital expenditures for 2014 are estimated to be approximately $170 million but could vary due to changes in exchange rates as well as the timing of capital projects.

We used $5.0 million in cash for financing activities during the first nine months of 2014 compared to $80.6 million during the same period a year ago.  The decrease in cash used by financing activities is due primarily to an increase in the proceeds from notes payable primarily used to cover dividends and share repurchases in 2014.

Cash and equivalents increased to $347.4 million at September 30, 2014 from $309.9 million at December 31, 2013.  Total short and long-term interest bearing debt also increased in the first nine months of 2014 to $602.1 million from $494.6 million at December 31, 2013.  The ratio of our Net Debt (interest bearing debt less cash and cash equivalents) to Net Capital (stockholder’s equity plus Net Debt) was 15.3% at the end of September 2014 compared to 11.1% at December 31, 2013.

Our U.S. operations generate sufficient cash flows to fund their liquidity needs and do not depend on cash located outside of the U.S. for their operations.  Nevertheless, we are a dividend payer and have an active share repurchase program.  These two items are funded with operating cash flows from the U.S. and are supplemented by additional borrowings from our revolving

 

21



Table of Contents

 

credit facility.  Specifically, in the U.S., we have an unsecured $300 million revolving line of credit of which $70 million was unused and available as of September 30, 2014 and we believe we have the ability to borrow additional funds should the need arise.  On January 31, 2013, we amended the revolving credit facility to, among other things, add a swingline loan sub-facility and extend the maturity date for the revolving credit facility by one year, to January 31, 2018.  On January 31, 2014, we amended the revolving credit facility to, among other things, increase the amount of permitted receivables transactions from $100 to $150 million, reduce the cost of committed funds by 12.5 basis points and uncommitted funds by 2.5 basis points, and extend the maturity date of the revolving credit facility by one year, to January 31, 2019.

Our revolving credit facility and certain long-term obligations require us to satisfy certain financial and other covenants including:

 

 

 

Requirement

 

Level at September 30, 2014

 

Debt to total capital ratio

 

Maximum of 55%

 

29.9%

 

 

Based upon the above debt to total capital ratio covenant, we had the ability to borrow approximately an additional $1.1 billion at September 30, 2014 before the 55% requirement would be exceeded.

Our foreign operations have historically met cash requirements with the use of internally generated cash or borrowings.  These foreign subsidiaries have financing arrangements with several foreign banks to fund operations located outside the U.S., but the majority of these arrangements are uncommitted.  Cash generated by foreign operations has generally been reinvested locally.  The majority of our $347.4 million in cash and equivalents is located outside of the U.S.  We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.  The repatriation of non-U.S. cash balances from certain subsidiaries could have adverse tax consequences as we may be required to pay and record income tax expense on these funds.  Historically, the tax consequences associated with repatriating current year earnings to the U.S. has been between 10% and 14% of the repatriated amount.  We would not expect future impacts to be materially different.

We believe we are in a strong financial position and have the financial resources to meet business requirements in the foreseeable future.  We have historically used cash flow from operations as our primary source of liquidity.  Our primary uses of liquidity are to invest in equipment and facilities that are necessary to support our growth and to make acquisitions that will contribute to the achievement of our strategic objectives.  In the event that customer demand would decrease significantly for a prolonged period of time and negatively impact cash flow from operations, we would have the ability to restrict and significantly reduce capital expenditure levels, as well as evaluate our acquisition strategy and dividend and share repurchase programs.  A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

On October 23, 2014, the Board of Directors declared a quarterly dividend of $0.28 per share payable on November 26, 2014 to stockholders of record as of November 5, 2014.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases expiring at various dates through the year 2027.  Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term.  Other than operating lease obligations, we do not have any off-balance sheet arrangements.

 

RECENTLY ISSUED ACCOUNTING STANDARDS

 

We have reviewed the recently issued accounting standards updates to the FASB’s Accounting Standards Codification that have future effective dates.  Standards which are effective for the first nine months of 2014 are discussed in Note 1 of the Unaudited Notes to Condensed Consolidated Financial Statements.

In May 2014, the FASB amended the guidance for recognition of revenue from customer contracts.  The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance will be effective for the Company’s fiscal year beginning after December 15, 2016.  Early application is not permitted.  We are currently evaluating the effect that the guidance will have on our financial statements.

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

 

OUTLOOK

 

We anticipate that the fourth quarter will be challenging. Consistent with recent macroeconomic indicators, certain markets in Latin America and Europe are expected to be weaker than recent quarters.  We do not see the U.S. growth trajectory in our markets changing dramatically. In addition, we face a difficult comparison to the strong fourth quarter of the prior year when we posted double-digit top-line growth and foreign currency exchange rates were much more favorable than they are today. Despite these challenges, the fundamentals of our end markets have not changed and we will stay focused on our strategic approach to these markets as we invest in innovative solutions that help our customers grow their businesses.

AptarGroup expects earnings per share for the fourth quarter using a 33% effective tax rate to be in the range of $0.58 to $0.63 per share compared to $0.54 per share reported in the prior year.  Comparable prior year earnings per share of $0.60 per share exclude the negative impacts of $0.05 per share from charges related to the European restructuring plan and $0.05 per share related to the net effect of several tax related items, and include a downward adjustment of $0.04 per share which is necessary to state the prior year earnings per share using foreign currency exchange rates as of September 30, 2014.

 

22



Table of Contents

 

FORWARD-LOOKING STATEMENTS

 

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, and Outlook sections of this Form 10-Q.  Words such as “expects,” “anticipates,” “believes,” “estimates,” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements.  Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us.  Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment, including but not limited to:

 

·

economic, environmental and political conditions worldwide;

·

financial conditions of customers and suppliers;

·

the cost of materials and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);

·

changes or consolidations within our customer base and/or changes in consumer spending levels;

·

the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;

·

our ability to contain costs and improve productivity;

·

our ability to successfully implement facility expansions and new facility projects, including the Stelmi expansion;

·

our ability to increase prices, contain costs and improve productivity;

·

significant fluctuations in foreign currency exchange rates, including the current volatility noted in the Latin American and Asian regions;

·

changes in capital availability or cost, including interest rate fluctuations;

·

volatility of global credit markets;

·

the timing and magnitude of capital expenditures;

·

our ability to identify potential new acquisitions and to successfully acquire and integrate such operations or products;

·

direct or indirect consequences of acts of war or terrorism;

·

cybersecurity threats that could impact our networks and reporting systems;

·

the impact of natural disasters and other weather-related occurrences;

·

fiscal and monetary policy, including changes in worldwide tax rates;

·

changes or difficulties in complying with government regulation;

·

changing regulations or market conditions regarding environmental sustainability;

·

work stoppages due to labor disputes;

·

competition, including technological advances;

·

our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;

·

the outcome of any legal proceeding that has been or may be instituted against us and others;

·

our ability to meet future cash flow estimates to support our goodwill impairment testing;

·

the demand for existing and new products;

·

our ability to manage worldwide customer launches of complex technical products, in particular in developing markets;

·

the success of our customers’ products, particularly in the pharmaceutical industry;

·

difficulties in product development and uncertainties related to the timing or outcome of product development;

·

significant product liability claims; and

·

other risks associated with our operations.

 

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.  Readers are cautioned not to place undue reliance on forward-looking statements.  We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  Please refer to Item 1A (“Risk Factors”) of Part I included in the Company’s Annual Report on Form 10-K for additional risk factors affecting the Company.

 

23



Table of Contents

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

A significant number of our operations are located outside of the United States.  Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities.  Our primary foreign exchange exposure is to the Euro, but we also have foreign exchange exposure to the Brazilian Real, British Pound and Swiss Franc, among others.  Recently we have experienced volatility in certain currencies, including the Argentine Peso, Brazilian Real, Indian Rupee and the Russian Ruble.  A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations.  Conversely, a weakening U.S. dollar has an additive effect.

Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred.  Any changes in exchange rates on such inter-country sales may impact our results of operations.

We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.

The table below provides information as of September 30, 2014 about our forward currency exchange contracts.  The majority of the contracts expire before the end of the fourth quarter of 2014.

 

 

 

 

 

 

Average

 

Min / Max

 

 

 

Contract Amount

 

Contractual

 

Notional

 

Buy/Sell

 

(in thousands)

 

Exchange Rate

 

Volumes

 

 

 

 

 

 

 

 

 

Swiss Franc/Euro

 

$

61,680

 

0.8275

 

60,652-62,207

 

Euro/U.S. Dollar

 

23,570

 

1.3204

 

19,591-23,570

 

Euro/Brazilian Real

 

18,773

 

3.3077

 

18,659-20,176

 

British Pound/Euro

 

9,591

 

1.252

 

8,504-9,591

 

Euro/Mexican Peso

 

9,587

 

18.6624

 

9,092-9,737

 

Czech Koruna/Euro

 

7,296

 

0.0363

 

5,863-7,296

 

Euro/Indian Rupee

 

5,495

 

86.2674

 

5,495-5,495

 

Euro/Colombian Peso

 

3,287

 

2,880.399

 

3,287-3,287

 

Euro/Chinese Yuan

 

2,817

 

8.2122

 

1,503-2,817

 

U.S. Dollar/Chinese Yuan

 

2,800

 

6.1946

 

2,800-8,030

 

Euro/Thai Baht

 

1,974

 

44.93

 

1,974-1,974

 

U.S. Dollar/Euro

 

1,770

 

0.7772

 

500-2,088

 

Euro/Indonesian Rupiah

 

1,667

 

16711

 

1,667-1,667

 

U.S. Dollar/Brazilian Real

 

1,137

 

2.3897

 

927-1,137

 

Mexican Peso/U.S. Dollar

 

1,080

 

0.0755

 

0-1,080

 

Euro/Russian Ruble

 

1,022

 

46.8264

 

1,022-1,022

 

Other

 

1,479

 

 

 

 

 

Total

 

$

155,025

 

 

 

 

 

 

As of September 30, 2014, we have recorded the fair value of foreign currency forward exchange contracts of $0.8 million in prepaid and other, $0.1 million in miscellaneous other assets, $3.0 million in accounts payable and accrued liabilities and $0.3 million in deferred and other non-current liabilities in the balance sheet.

 

ITEM 4.  CONTROLS AND PROCEDURES

 

DISCLOSURE CONTROLS AND PROCEDURES

 

The Company’s management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of the Company’s disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of September 30, 2014.  Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

 

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

No changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during the Company’s fiscal quarter ended September 30, 2014 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

24



Table of Contents

 

PART II - OTHER INFORMATION

 

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

RECENT SALES OF UNREGISTERED SECURITIES

 

The employees of AptarGroup S.A.S. and Aptar France S.A.S., our subsidiaries, are eligible to participate in the FCP Aptar Savings Plan (the “Plan”).  All eligible participants are located outside of the United States.  An independent agent purchases shares of our common stock available under the Plan for cash on the open market and we do not issue shares.  We do not receive any proceeds from the purchase of shares of our common stock under the Plan.  The agent under the Plan is Banque Nationale de Paris Paribas Fund Services.  No underwriters are used under the Plan.  All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act.  During the quarter ended September 30, 2014, the Plan purchased 1,350 shares of our common stock on behalf of the participants at an average price of $61.38 per share, for an aggregate amount of $82.9 thousand, and sold 850 shares of our common stock on behalf of the participants at an average price of $63.50 per share, for an aggregate amount of $54.0 thousand.  At September 30, 2014, the Plan owns 49,536 shares of our common stock.

 

ISSUER PURCHASES OF EQUITY SECURITIES

 

The following table summarizes the Company’s purchases of its securities for the quarter ended September 30, 2014:

 

 

Period

 

 

Total Number
Of Shares
Purchased

 

Average Price
Paid Per Share

 

Total Number Of Shares
Purchased As Part Of
Publicly Announced

Plans Or Programs

 

Maximum Number Of
Shares That May Yet Be
Purchased Under The

Plans Or Programs

 

 

 

 

 

 

 

 

 

 

 

7/1 – 7/31/14

 

162,500

 

$

62.72

 

162,500

 

3,010,191

 

8/1 – 8/31/14

 

437,500

 

62.72

 

437,500

 

2,572,691

 

9/1 – 9/30/14

 

--

 

--

 

--

 

2,572,691

 

Total

 

600,000

 

$

62.72

 

600,000

 

2,572,691

 

 

The Company announced the repurchase program in effect for the quarter ended September 30, 2014 on July 18, 2013, which authorized the Company to repurchase up to four million shares of our outstanding common stock.  There is no expiration date for this repurchase program.  On October 30, 2014, the Company announced a new share repurchase authorization of up to $350 million of common stock.  This new authorization replaces previous authorizations and has no expiration date.  AptarGroup may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

 

ITEM 6.  EXHIBITS

 

Exhibit 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

Exhibit 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

Exhibit 32.2

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

Exhibit 101

The following financial information from our Quarterly Report on Form 10-Q for the third quarter of fiscal 2014, filed with the SEC on November 6, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income - Three and Nine Months Ended September 30, 2014 and 2013, (ii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2014 and 2013, (iii) the Condensed Consolidated Balance Sheets – September 30, 2014 and December 31, 2013, (iv) the Condensed Consolidated Statements of Changes in Equity - Nine Months Ended September 30, 2014 and 2013, (v) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2014 and 2013 and (vi) the Notes to Condensed Consolidated Financial Statements.

 

25



Table of Contents

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

AptarGroup, Inc.

 

(Registrant)

 

 

 

By /s/ ROBERT W. KUHN

 

Robert W. Kuhn

 

Executive Vice President,

 

Chief Financial Officer and Secretary

 

(Duly Authorized Officer and

 

Principal Accounting and Financial Officer)

 

 

 

 

 

Date: November 6, 2014

 

26



Table of Contents

 

INDEX OF EXHIBITS

 

Exhibit

 

 

Number

 

Description

 

 

 

31.1

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101

 

The following financial information from our Quarterly Report on Form 10-Q for the third quarter of fiscal 2014, filed with the SEC on November 6, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income - Three and Nine Months Ended September 30, 2014 and 2013, (ii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2014 and 2013, (iii) the Condensed Consolidated Balance Sheets – September 30, 2014 and December 31, 2013, (iv) the Condensed Consolidated Statements of Changes in Equity - Nine Months Ended September 30, 2014 and 2013, (v) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2014 and 2013 and (vi) the Notes to Condensed Consolidated Financial Statements.